RTS Life Science Automation Chosen to Increase UK Biobank Sample Processing Capability
News Aug 24, 2009
RTS Life Science has announced that they have been selected to supply four Saliva and RNA Stabilized Blood Processing Systems to the UK Biobank.
UK Biobank, a project aiming to advance public health in the 21st Century, was officially opened by Princess Anne on 28th July 2009, and is now over half way through its collection of participant samples across the UK. An additional two samples, saliva and blood for RNA isolation, will be collected from the remaining participants and the new RTS automation will allow up to 800 samples to be processed per day.
RTS originally supplied a High Throughput Blood fractionation system for UK Biobank to process centrifuged EDTA, serum separator and plasma separator tubes, enabling the retrieval of the plasma, serum, buffy coat and red blood cells. Since the implementation of these systems, two years ago, RTS has released a 2nd generation ‘blood fractionation’ system (ABF500).
The ABF system has now been refined so that it can process saliva and RNA stabilized blood samples with only minimal instrument preparation required to run either sample type. The user only needs to change the deck layout and select the correct software process.
The new ASP (Automated Sample Processor) 800 will process up to 800 saliva or RNA stabilized blood samples per day into 2 and 6 850ul aliquots respectively. RTS’ eSprint software will provide complete sample tracking and the production of a full audit trail.
Paul Downey, Director of Operations at UK Biobank comments, “The technical support provided by RTS and collaborative approach to solution development has meant that UK Biobank has consistently met its demanding production targets and we are pleased to have them as a long term partner.”
RNAi-based Drug Shows Promise as Treatment for Chronic Hepatitis BNews
The novel therapy by Arrowhead Pharmaceuticals uses a mechanism called RNA interference to reduce the surface antigens created by chronic HBV infections.READ MORE
A More Effective Alternative to RNAi, CRISPR for Studying Protein FunctionNews
Trim-Away is a novel method enabling researchers to directly and rapidly destroy any protein in any kind of cell.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE